| Market Cap | 247.50M | P/E | - | EPS this Y | 22.90% | Ern Qtrly Grth | - |
| Income | -207.73M | Forward P/E | -0.67 | EPS next Y | -15.90% | 50D Avg Chg | 17.00% |
| Sales | 53.01M | PEG | -0.02 | EPS past 5Y | - | 200D Avg Chg | -12.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 38.00% | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 4.45 | Shares Outstanding | 168.36M | 52W Low Chg | 258.00% |
| Insider Own | 0.58% | ROA | -39.25% | Shares Float | 135.37M | Beta | -0.42 |
| Inst Own | 81.05% | ROE | -877.48% | Shares Shorted/Prior | 2.34M/4.74M | Price | 1.47 |
| Gross Margin | 79.64% | Profit Margin | - | Avg. Volume | 4,125,541 | Target Price | 6.00 |
| Oper. Margin | -365.32% | Earnings Date | Nov 7 | Volume | Change | 0.00% |
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
| Cowen & Co. | Market Perform | Jun 28, 22 |
| Wedbush | Neutral | Jun 27, 22 |
| HC Wainwright & Co. | Buy | Jun 3, 22 |
| HC Wainwright & Co. | Buy | May 12, 22 |
| HC Wainwright & Co. | Buy | Mar 2, 22 |
| Morgan Stanley | Underweight | Aug 10, 21 |
| HC Wainwright & Co. | Buy | Aug 10, 21 |
| Morgan Stanley | Equal-Weight | May 7, 21 |
| SVB Leerink | Outperform | May 7, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bogle Grant C. | See Remarks See Remarks | Aug 09 | Option | 1.4 | 1,217,500 | 1,704,500 | 654,253 | 08/11/22 |
| Agarwal Shefali | Other Other | Aug 09 | Option | 1.39 | 500,000 | 695,000 | 658,716 | 08/11/22 |
| Beaulieu Joseph | See Remarks See Remarks | Aug 09 | Option | 1.39 | 300,000 | 417,000 | 330,963 | 08/11/22 |
| Kutok Jeffery | Chief Scientific Off.. Chief Scientific Officer | Aug 09 | Option | 1.39 | 380,000 | 528,200 | 474,563 | 08/11/22 |
| Kutok Jeffery | Chief Scientific Off.. Chief Scientific Officer | Apr 11 | Sell | 0.90 | 2,741 | 2,467 | 94,563 | 04/13/22 |
| Beaulieu Joseph | Corporate Controller Corporate Controller | Feb 07 | Sell | 1.50 | 222 | 333 | 28,632 | 02/09/22 |
| Agarwal Shefali | See Remarks See Remarks | Feb 07 | Sell | 1.50 | 1,058 | 1,587 | 156,385 | 02/09/22 |
| Agarwal Shefali | See Remarks See Remarks | Jan 26 | Sell | 2.02 | 2,922 | 5,902 | 160,082 | 01/28/22 |
| Beaulieu Joseph | Corporate Controller Corporate Controller | Sep 03 | Sell | 12.83 | 1,514 | 19,425 | 5,958 | 09/03/20 |